Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

The treatment of acute tendon injury with small extracellular vesicles originating from TNFAIP6 - ADSCs subpopoulation both in vitro and in vivo.

Liu H., Zhang A., Shi M., Zhang J., Zhang T., Lu W.

Animal Study on Tendon Injury, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41469712
PMCID
PMC12866520
DOI
10.1186/s13287-025-04789-2

Abstract (original English)

Background Small extracellular vesicles originating from adipose-derived mesenchymal stromal cells (ADSC-sEVs) have excellent therapeutic value in acute tendon injury. However, their mechanism and effects have not been fully elucidated. This study aimed to identify the key subsets and mechanisms of action of ADSC-sEVs involved in the repair of complete tendon tear caused by acute injury. Methods Based on our previous research demonstrating that ADSC-sEVs improve the quality of acute tendon injury repair, the present study utilized second-generation sequencing and bioinformatics to predict the key role of the TNFAIP6 - ADSC subgroup in acute tendon injury repair. We constructed different ADSC-sEVs through ADSC transfection and treated tendon stem cells for further exploration. EdU, cell scratch, and Transwell assays were used to evaluate cell proliferation and migration in vitro. Western blot and quantitative real-time polymerase chain reaction analyses were performed. Histopathological, immunohistochemical, and biomechanical testing were used for in vivo validation. Results TNFAIP6 - ADSC-sEVs significantly improved the therapeutic effect of ADSC-sEVs on acute tendon injury, which was related to the high expression of let-7c-5p. Application of different ADSC-sEVs in vitro and in vivo identified CRCT1/JAK2/STAT3 as a key downstream signaling pathway regulated by let-7c-5p. Concl

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsExtracellular VesiclesMesenchymal Stem CellsTendon InjuriesHumansCell ProliferationMiceMaleMicroRNAsCell Movement

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research